Drug Profile
XomaZyme-Mel
Alternative Names: antimelanoma antibody-ricin A conjugateLatest Information Update: 29 Jun 1999
Price :
$50
*
At a glance
- Originator XOMA
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 29 Jun 1999 Discontinued-II for Malignant melanoma in USA (IV-infusion)
- 29 May 1997 No-Development-Reported for Malignant melanoma in USA (IV-infusion)
- 29 May 1995 Phase-II clinical trials for Malignant melanoma in USA (IV-infusion)